News|Articles|April 1, 2025

Q1 2025 Recap: Endocrinology News and Updates

Our Q1 2025 recap for endocrinology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in diabetes care.

The field of endocrinology, particularly diabetes care, has surged forward in recent years, reshaping patient outcomes with groundbreaking therapies and technology. From pharmacotherapy advances transcending the public consciousness to continuous glucose monitoring to AI-driven insulin delivery, innovation has redefined what is possible.

Related to this article

Robert Mentz, MD | Image Credit: American Heart Association

November 5th, 2026

Moving the Needle in Medicine: Mentorship, Teams, and Heart Failure Leadership, With Robert Mentz, MD

Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.

November 3rd, 2026

8 Hepatology Headlines You Missed in October 2026

October 2026 hepatology news includes FDA approval of bepirovirsen for hepatitis B, new ACLF criteria, ACG cirrhosis guidance, and MASH trial data.

November 3rd, 2026

8 Nephrology Headlines You Missed in October 2026

Nephrology in October 2026: FDA approves ravulizumab for IgAN, plus ORIGIN 3, RAINIER, TELIGAN, and ATTACK data from Kidney Week.

October 31st, 2026

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.

November 5th, 2026

Once-Daily Trientine Tetrahydrochloride Aids Adherence in Wilson Disease

In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.

November 5th, 2026

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.

November 5th, 2026

Real-World Odevixibat Data Show Pruritus Relief in Late-Onset PFIC

In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.

November 5th, 2026

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.